Literature DB >> 29330403

Ruxolitinib in steroid-refractory chronic graft-versus-host disease: experience of a single center.

Aliana Meneses Ferreira1, Carolina Atallah Pontes da Silva2, André Domingues Pereira2, Roberta Shcolnik Szor2, Ana Rita Brito Medeiros da Fonseca2, Mariana Gomes Serpa2, Erick Menezes Xavier2, Michelly Kerly Sampaio de Melo2, Yana Novis2, Luciana Tucunduva2, Vanderson Rocha2, Celso Arrais-Rodrigues2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29330403     DOI： 10.1038/s41409-017-0068-2

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  8 in total

1.  Ruxolitinib is an effective salvage treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation without posttransplant cyclophosphamide.

Authors:  Jiao-Yu Zhao; Si-Ning Liu; Lan-Ping Xu; Xiao-Hui Zhang; Yu Wang; Yu-Hong Chen; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Dong Mo
Journal:  Ann Hematol       Date:  2020-11-07       Impact factor: 3.673

2.  Persistent polyomavirus-associated nephropathy in a patient with GvHD and treatment with the JAK1/2 inhibitor ruxolitinib.

Authors:  Matthias A Fante; Ernst Holler; Barbara Schmidt; Daniel Wolff; Yvonne Ehrl; Annelie Plentz
Journal:  Bone Marrow Transplant       Date:  2018-10-22       Impact factor: 5.483

3.  Ruxolitinib treatment for bronchiolitis obliterans syndrome following hematopoietic stem cell transplant in a patient with primary hemophagocytic lymphohistiocytosis.

Authors:  Guang-Qiang Meng; Yi-Ni Wang; Jing-Shi Wang; Zhao Wang
Journal:  Chin Med J (Engl)       Date:  2021-01-05       Impact factor: 2.628

4.  The Effectiveness of Ruxolitinib for Acute/Chronic Graft-versus-Host Disease in Children: A Retrospective Study.

Authors:  Wenli Yang; Guanghua Zhu; Maoquan Qin; Zhigang Li; Bin Wang; Jun Yang; Tianyou Wang
Journal:  Drug Des Devel Ther       Date:  2021-02-22       Impact factor: 4.162

Review 5.  Janus Kinase Inhibitors and Cell Therapy.

Authors:  Amer Assal; Markus Y Mapara
Journal:  Front Immunol       Date:  2021-08-31       Impact factor: 7.561

6.  Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients.

Authors:  Cong Wei; Xiaoting Zhang; Dan Liang; Jilong Yang; Jingwen Du; Chunyan Yue; Lan Deng
Journal:  Drug Des Devel Ther       Date:  2021-11-30       Impact factor: 4.162

7.  Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement.

Authors:  Martina Kaurinovic; Konstantina Delli; Ana-Mae E Jonk; Anouschka Biswana; Carin L E Hazenberg; Goda Choi; Marco R de Groot; Linde M Morsink; Arjan Vissink; Mar Bellido
Journal:  Clin Oral Investig       Date:  2022-02-16       Impact factor: 3.606

8.  Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies.

Authors:  Meng-Yun Zhang; Peng Zhao; Yan Zhang; Ji-Shi Wang
Journal:  PLoS One       Date:  2022-07-29       Impact factor: 3.752
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.